Brainstorm Cell Therapeutics IncNASDAQ:BCLI
- LAST PRICE2.9400
- TODAY'S CHANGE (%)0.0900 (3.1579%)
- Bid / Lots2.8700/ 1
- Ask / Lots3.0000/ 7
- Open / Previous Close2.8300 / 2.8500
- Day Range
- 52 Week Range
- Volume42,845
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCLI |
|---|---|---|
| 09:32 ET | 1029 | 2.84 |
| 09:36 ET | 975 | 2.87 |
| 09:41 ET | 500 | 2.87 |
| 09:52 ET | 500 | 2.87 |
| 10:12 ET | 100 | 2.865 |
| 10:15 ET | 100 | 2.811 |
| 10:26 ET | 200 | 2.8251 |
| 10:28 ET | 100 | 2.8597 |
| 10:30 ET | 100 | 2.835 |
| 10:35 ET | 1700 | 2.86 |
| 10:57 ET | 800 | 2.845 |
| 11:02 ET | 500 | 2.8316 |
| 11:08 ET | 910 | 2.85 |
| 11:09 ET | 525 | 2.83 |
| 11:13 ET | 1000 | 2.85 |
| 11:18 ET | 100 | 2.8323 |
| 11:22 ET | 100 | 2.831 |
| 11:24 ET | 450 | 2.85 |
| 11:27 ET | 100 | 2.83 |
| 11:29 ET | 100 | 2.835 |
| 11:33 ET | 575 | 2.83 |
| 11:40 ET | 100 | 2.82 |
| 11:42 ET | 100 | 2.81 |
| 11:49 ET | 180 | 2.8166 |
| 11:54 ET | 4170 | 2.84 |
| 11:58 ET | 100 | 2.84 |
| 12:07 ET | 100 | 2.845 |
| 12:09 ET | 300 | 2.86 |
| 12:12 ET | 100 | 2.89 |
| 12:27 ET | 476 | 2.89 |
| 12:36 ET | 250 | 2.8899 |
| 12:38 ET | 1900 | 2.8701 |
| 12:39 ET | 1300 | 2.89 |
| 12:43 ET | 100 | 2.87 |
| 12:48 ET | 100 | 2.875 |
| 12:54 ET | 600 | 2.89 |
| 12:57 ET | 500 | 2.89 |
| 01:03 ET | 100 | 2.8998 |
| 01:06 ET | 800 | 2.88 |
| 01:10 ET | 100 | 2.89 |
| 01:14 ET | 500 | 2.8713 |
| 01:24 ET | 100 | 2.89 |
| 01:37 ET | 150 | 2.875 |
| 02:09 ET | 100 | 2.861 |
| 02:20 ET | 1000 | 2.9 |
| 02:22 ET | 100 | 2.93 |
| 02:29 ET | 100 | 2.92 |
| 02:36 ET | 100 | 2.915 |
| 02:42 ET | 941 | 2.93 |
| 02:44 ET | 100 | 2.94 |
| 03:12 ET | 100 | 2.94 |
| 03:14 ET | 100 | 2.94 |
| 03:18 ET | 300 | 2.94 |
| 03:21 ET | 100 | 2.96 |
| 03:27 ET | 1538 | 2.96 |
| 03:36 ET | 100 | 2.956 |
| 03:38 ET | 200 | 2.95 |
| 03:39 ET | 516 | 2.94 |
| 03:41 ET | 100 | 2.93 |
| 03:43 ET | 1611 | 2.92 |
| 03:52 ET | 100 | 2.925 |
| 03:54 ET | 364 | 2.925 |
| 03:56 ET | 100 | 2.925 |
| 03:57 ET | 2001 | 2.905 |
| 03:59 ET | 1860 | 2.94 |
May 25, 2023
Brainstorm Cell Therapeutics Chief Operating Officer David Setboun Resigns, from 3:32AM ET on Thursday May 25, 2023 by MT Newswires
3:32AM ET on Thursday May 25, 2023 by MT Newswires
May 19, 2023
May 15, 2023
BRIEF-Brainstorm Cell Therapeutics Announces First Quarter 2023 Financial Results , from 7:16AM ET on Monday May 15, 2023 by Thomson Reuters
7:16AM ET on Monday May 15, 2023 by Thomson ReutersBrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update, from 7:05AM ET on Monday May 15, 2023 by PR Newswire
7:05AM ET on Monday May 15, 2023 by PR Newswire
May 9, 2023
BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update, from 6:00AM ET on Tuesday May 09, 2023 by PR Newswire
6:00AM ET on Tuesday May 09, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Brainstorm Cell Therapeutics Inc | 115.9M | -4.5x | --- |
Pardes Biosciences Inc | 117.3M | -1.2x | --- |
Talaris Therapeutics Inc | 117.2M | -1.5x | --- |
Genenta Science SPA | 109.6M | -12.1x | --- |
Shattuck Labs Inc | 115.5M | -1.2x | --- |
GlycoMimetics Inc | 118.9M | -2.4x | --- |
Company Information
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimers disease (AD) and other neurodegenerative diseases. NurOwn, the Company’s cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its Phase III ALS and Phase II PMS clinical trials. Its wholly owned Israeli subsidiary, BrainStorm Cell Therapeutics Ltd., holds rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd. and two others.
Contact Information
- Headquarters
- 1325 Avenue Of Americas, 28Th FloorNEW YORK, NY, United States 10019
- Phone
- 201-488-0460
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jacob Frenkel
- President, Chief Executive Officer
- Chaim Lebovits
- Co-Chief Executive Officer
- Stacy Lindborg
- Independent Vice Chairman of the Board
- Irit Arbel
- Chief Financial Officer, Controller
- Alla Patlis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $115.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.42 |
EPS | $-0.66 |
Book Value | $-0.08 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
